Human Regenerative Technologies (HRT) Receives Q-Code Status for 2016 for Outpatient Wound Care Applications

Share Article

These Q-codes create a significant asset for the company, as HRT continues to expand its private label partnerships with synergistic medical companies in various markets. Human Regenerative Technologies (HRT) aims to provide the highest quality human tissue allografts and has developed the industry’s most diverse line of active amniotic and placental based biologics utilizing our proprietary HydraTek® process.

News Image
“HRT is excited to receive these unique HCPCS Q-Codes for both our amniotic membranes and flowable placental tissue matrix part of our exclusive Advanced Woundcare line as it opens up the approximately $500 million skin substitute mkt." Chris Sharp

Human Regenerative Technologies LLC (HRT®) is a regenerative solutions biomedical company engaged in the development and commercialization of novel human-based active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues, which are exclusively processed by the proprietary HydraTek® Process.

“HRT is very excited to receive these unique Level II HCPCS Q-Codes for both our amniotic membranes and flowable placental tissue matrix as part of our exclusive Advanced Woundcare line as it opens up the approximately $500 million skin substitute sector of the advanced wound care market, part of the $7 billion plus addressable wound care market, to our distribution channels and select partnerships.”

"Independent studies have shown HRT biologics are demonstrating to be an ideal solution for the treatment of many wounds and surgical challenges,” commented Chris Sharp, CEO. “We have developed one of the industry’s most diverse active amniotic biologic lines through our proprietary HydraTek® Process that has been validated to preserve the native biologic components found in unprocessed placentas, and we are thrilled to be sharing them with the wound care community. Our mission continues to be advancing our line of novel placental tissue-based products with the goal of enhancing the quality of patient care in a broad range of clinical applications.”

These Q-codes create a significant asset for the company, as HRT continues to expand its private label partnerships with synergistic medical companies in various markets.

About Human Regenerative Technologies, LLC (HRT). Harnessing the Regenerative Power of the Body®:

Human Regenerative Technologies, LLC (HRT®) is a regenerative biologics company, focused on advancing the understanding and development of human cellular and protein-based therapies through scientific and clinical application.

Human Regenerative Technologies (HRT) aims to provide the highest quality human tissue allografts and has developed the industry’s most diverse line of active amniotic and placental based biologics utilizing our proprietary HydraTek® process. The comprehensive HydraTek® product line provides physicians with a distinct advantage in both handling and performance. HydraTek® membrane products are available in thin and thick configurations, and provide unique structural integrity and handling characteristics. HydraTek® flowable products are available with cryopreserved or ambient (room) temperature storage, and allow precise targeting and delivery to the intended site.

HRT's commercially available regenerative biologics successfully combine precise science and technology in the procurement, processing and delivery of innovative and novel active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues.

HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.

For more information, visit our website at http://www.humantissue.com or email: info(at)humantissue(dot)com

Forward-looking statement
Any forward-looking statement is based on information available to Human Regenerative Technologies LLC as of the date of the statement. All written or oral forward-looking statements attributable to Human Regenerative Technologies LLC are qualified by this caution. HRT does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in HRT’s expectations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website